13F Holdings
中文EN

NRXP NRX Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1719406 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,076.5%
TTM net income YoY48.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin40.5%
Operating margin-551.7%
Net margin-454.1%
FCF margin—
EBITDA margin-546.4%

Returns

ROE—
ROA-92.3%
ROIC (approx.)—
Asset turnover0.20x

Leverage & solvency

Liabilities / assets107.1%
Debt / equity—
Current ratio0.76x
Interest coverage-17.37x

Cash quality & payout

Operating cash flow / net income1.19x
Accruals ratio17.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.23M$0$0——
Cost of revenue$505,000$0———
Gross profit$720,000$0———
R&D expense$3.78M$6.20M$13.37M$17.03M$20.26M
SG&A expense$13.06M$13.50M$14.22M$27.31M$74.94M
Operating income-$16.22M-$18.50M-$27.84M-$44.34M-$115.80M
Interest expense$671,000$230,000$120,000—$18,000
Pretax income———-$39.75M-$93.06M
Income tax$0$0$0——
Net income-$28.62M-$25.13M-$30.15M-$39.75M-$93.06M
EBITDA-$16.15M-$18.50M-$27.83M-$44.33M-$115.79M
EPS (basic)-1.34-2.36-3.98-0.60-1.98
EPS (diluted)———-0.60-1.98
Weighted avg. shares (diluted)———65.77M46.92M
Balance sheet
Cash & equivalents$7.80M$1.44M$4.59M$20.05M$27.61M
Receivables$161,000$0———
Current assets$8.89M$3.30M$6.88M$25.80M$32.71M
PP&E, net$63,000$10,000———
Goodwill$1.79M$0———
Intangibles$925,000$0———
Total assets$12.96M$3.65M$7.32M$25.82M$32.73M
Current liabilities$28.58M$21.86M$19.05M$15.59M$11.92M
Short-term debt——$9.16M$7.70M—
Long-term debt——$9.16M$2.82M—
Total debt——$18.32M$10.53M—
Total liabilities$28.89M$26.87M$19.05M$18.41M$11.92M
Shareholders' equity-$15.94M-$23.22M-$11.73M$7.41M$20.81M
Net debt——$13.73M-$9.53M—
Shares outstanding31.73M14.59M8.39M66.44M58.81M
Cash flow statement
Operating cash flow-$14.11M-$10.64M-$21.66M-$39.76M-$37.70M
Capital expenditure—$0$3,000$10,000$7,000
Free cash flow—-$10.64M-$21.66M-$39.77M-$37.71M
Investing cash flow-$2.81M$0-$3,000-$10,000-$7,000
Financing cash flow$23.28M$7.49M$6.20M$32.21M$63.46M
Depreciation & amortization$70,000$5,000$5,000$4,000$2,000
Stock-based compensation$228,000$486,000$387,000$3.63M$7.79M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.